Chair, Cancer Center Directors

Howard H. Bailey, MD, is the director of the University of Wisconsin Carbone Cancer Center and a professor of Medicine at the UW School of Medicine and Public Health. Dr. Bailey’s clinical expertise is in sarcomas and gynecologic malignancies and his research focus is in anti-cancer drug development, especially chemoprevention, and research network development. Dr. Bailey also leads the UWCCC Chemoprevention Scientific Program and Chemoprevention Disease Orientated Work Group. He was appointed to the national committee which reviews all NCI-designated Cancer Centers in 2011.

Chair, Big Ten Cancer Research Consortium Foundation

Raphael E. Pollock, MD, PhD, is director of the Ohio State University Comprehensive Cancer Center and holds the Klotz Chair in Cancer Research. He is also a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on the molecular drivers underlying soft tissue sarcoma, a cancer of connective tissues that occurs throughout the body. Dr. Pollock has authored or co-authored more than 400 original research and review articles as well as 21 books. He has shared his work in over 300 national and international presentations and visiting professorships involving professional audiences in 50 countries worldwide.

Chief Scientific Officer

Monika Joshi, MD, MRCP, is a professor in the Division of Hematology-Oncology in Department of Medicine at the Penn State Cancer Institute (PSCI). She serves as disease team co-leader for the genitourinary diseases group at the PSCI and as medical director for the PSCI Clinical Trials Office. Her clinical and research interests lie primarily in the field of genitourinary tumors, particularly in the field of immunotherapy and targeted therapy. She has an interest in developing clinical trials with novel immunotherapeutic combinations and identifying predictive and prognostic biomarkers. Dr. Joshi has been active in the Big Ten CRC since the consortium’s founding in 2013. In addition to leading multiple Big Ten CRC studies, she served on the Big Ten CRC Steering Committee and as a co-chair the Genitourinary Clinical Trial Working Group.

Steering Committee

The Big Ten CRC Steering Committee is composed of one researcher from each member institution. The Steering Committee meets on a regular basis to review activities of the consortium and decide matters of policy. The Steering Committee determines the criteria for approving concepts for development with the Big Ten CRC.